RESEARCH TRIANGLE PARK, N.C. – February 16, 2010 – Quintiles today announced the availability of anatomic pathology services through its central laboratory in Beijing, China, to help biopharmaceutical companies develop more effective cancer treatments. These services complement assay development, digital pathology and core lab offerings available through the facility to help customers comply with China’s restrictions on tissue import/export.

“Within China, we are providing the tools and infrastructure to investigate cancer and match patients with optimum treatments for their genetic makeup,” said Christopher Ung, Vice President Strategic Business and Operations, Oncology for Quintiles. “These capabilities enable personalized medicine and enhance oncology research to bring medicines to market faster.”

Quintiles is a leader in developing novel biomarker assays to support clinical development of targeted therapies and other personalized medicine advances. Today, at labs in China, Scotland and the United States, Quintiles can perform Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) testing. In addition, Quintiles’ biomarker tests – such as PI3K, PTEN, HER2, EGFR and MET – are used to target genes that affect cancer cell growth and mutation. Quintiles is the only laboratory that has validated numerous assays for PI3K, including PI3K amplification, PI3K mutational analysis, PTEN IHC and others.

“The China anatomic pathology lab and continued biomarker assay development will help our customers navigate risk and seize opportunities in the New Health – which we see as an era of unprecedented change in the biopharma industry,” said Thomas Wollman, Senior Vice President, Global Central Labs. “The new China facility is part of our globally harmonized lab network.”

Affirming Quintiles’ commitment to patient safety and accurate clinical trial data, the Beijing anatomic pathology lab was accredited by the College of American Pathologists (CAP). The central lab at the Beijing site had previously received CAP accreditation, which follows an on-site evaluation by a team of practicing laboratory professionals who examine records, quality control, staff qualifications, equipment, safety, and overall site management.

Quintiles has the largest CAP accredited central lab network in the world, with nine facilities: in Argentina, Brazil, China, India, Japan, Singapore, Scotland, South Africa and the United States.

About Quintiles
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of 23,000 engaged professionals in more than 50 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.